{
    "nct_id": "NCT04044859",
    "official_title": "A Phase 1 Dose Escalation Study to Assess Safety and Efficacy of ADP-A2M4CD8 As Monotherapy or in Combination with Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects with MAGE-A4 Positive Tumors (SURPASS)",
    "inclusion_criteria": "* Key Inclusion criteria\n* Age ≥18 and ≤ 75 years\n* Subject is positive for at least 1 HLA-A*02 inclusion allele\n* Histologically or cytogenetically confirmed diagnosis of urothelial cancer, esophageal, esophagogastric junction (EGJ) cancer, gastric cancer, non-small cell lung carcinoma (NSCLC), head and neck or ovarian cancer, endometrial cancer, melanoma\n* Measurable disease according to RECIST v1.1 prior to leukapheresis and lymphodepletion.\n* Tumor shows MAGE-A4 expression as confirmed by central laboratory\n* ECOG Performance Status of 0 or 1.\n* Left ventricular ejection fraction (LVEF) ≥50% or the institutional lower limit of normal range, whichever is lower Note: other protocol defined Inclusion/Exclusion criteria may apply\n* Subjects must have ≥ 90% room air oxygen saturation at rest at Screening (within 7 days of leukapheresis) and at Baseline.\n\nKey exclusion criteria\n\n* Positive for any HLA-A*02 allele other than: one of the inclusion alleles\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to fludarabine, cyclophosphamide or other agents used in the study\n* Active autoimmune or immune mediated disease\n* Leptomeningeal disease, carcinomatous meningitis or symptomatic CNS metastases\n* Other prior malignancy that is not considered by the Investigator to be in complete remission. Clinically significant cardiovascular disease\n* Uncontrolled intercurrent illness\n* Active infection with human immunodeficiency virus, hepatitis B virus, hepatitis C virus, or human T cell leukemia virus\n* Pregnant or breastfeeding\n\nNote: other protocol defined Inclusion/Exclusion criteria may apply.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}